| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/22/2006 | EP1627636A1 Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| 02/22/2006 | EP1627633A1 Oral pharmaceutical forms of administration with a delayed action with tramadol |
| 02/22/2006 | EP1627631A2 Morphine sulphate microgranules, method for preparing same and composition comprising same |
| 02/22/2006 | EP1626980A1 Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| 02/22/2006 | EP1626971A1 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines |
| 02/22/2006 | EP1626967A1 Substituted pyrazoles |
| 02/22/2006 | EP1626965A1 Pyrazinones as crf1 receptor antagonists for the treatment of cns disorders |
| 02/22/2006 | EP1626959A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 02/22/2006 | EP1626958A1 (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht 1f agonists |
| 02/22/2006 | EP1626732A2 Means for preventing and treating cellular death and their biological applications |
| 02/22/2006 | EP1626727A1 Application of 2-cyano-10- (2-methyl-3- (methylamino)- propyl) phenothiazine or a pharmaceutically acceptable salt as medicament |
| 02/22/2006 | EP1626726A2 Use of lornoxicam or lornoxicam analogue compounds |
| 02/22/2006 | EP1626723A1 Treatment of bipolar disorders and associated symptoms |
| 02/22/2006 | EP1626722A1 Method for enhancing cognition using ziprasidone |
| 02/22/2006 | EP1626720A1 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
| 02/22/2006 | EP1626710A1 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders |
| 02/22/2006 | EP1626709A1 Enantiomeric amphetamine compositions for the treatment of adhd |
| 02/22/2006 | EP1626697A2 Pharmaceutical compositions for oral administration comprising lithium carbonate |
| 02/22/2006 | EP1626648A2 Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer s disease |
| 02/22/2006 | EP1456210B1 Pyrazolyl-substituted triazoloquinoxalines |
| 02/22/2006 | EP1414812B1 Hydroxamic acid derivatives |
| 02/22/2006 | EP1406622B1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/22/2006 | EP1402005A4 A method of purification of cells |
| 02/22/2006 | EP1385839B1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 02/22/2006 | EP1244805B1 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 02/22/2006 | EP1237874B1 Selective neurokinin antagonists |
| 02/22/2006 | EP1233957B1 Novel amidine derivatives, preparation and use thereof as medicines |
| 02/22/2006 | EP1224187B1 Certain alkylene diamine-substituted heterocycles |
| 02/22/2006 | EP1194584B1 Method for producing oligopolysaccharides |
| 02/22/2006 | EP1040185B1 Neural precursor cells, method for the production and use thereof in neural defect therapy |
| 02/22/2006 | EP0787206B1 USE OF NEURITE LOCALIZED mRNAs FOR MEDICAL DIAGNOSIS AND THERAPEUTICS |
| 02/22/2006 | CN1738827A Novel ampiphilic derivatives of alpha-c-phenyl n-tert-butyl nitrone |
| 02/22/2006 | CN1738821A Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 02/22/2006 | CN1738820A Novel diazabicyclic aryl derivatives |
| 02/22/2006 | CN1738819A 4-oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors |
| 02/22/2006 | CN1738806A Oxo-azabicyclic compounds |
| 02/22/2006 | CN1738788A Substituted phenyl naphthalenes as estrogenic agents |
| 02/22/2006 | CN1738782A Deuterated catecholamine derivatives and medicaments comprising said compounds |
| 02/22/2006 | CN1738625A Benzo (1,2,5) thiadiazole ALS CRF-antagonisten |
| 02/22/2006 | CN1738618A Pharmaceutical compositions and their uses |
| 02/22/2006 | CN1738611A Alpha-aminoamide derivatives useful as antimigraine agents |
| 02/22/2006 | CN1738608A Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders |
| 02/22/2006 | CN1738599A Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/22/2006 | CN1737007A Gastrodine derivative, its preparation method, pharmaceutical composition and uses |
| 02/22/2006 | CN1736485A Use of vanillin receptor agonist in preparation of product for resisting Alzheimer disease |
| 02/22/2006 | CN1736472A Depression treating medicinal formulation and its preparation process |
| 02/22/2006 | CN1736465A Apparatus and method for manufacturing tabasheer |
| 02/22/2006 | CN1736464A Medicine for treating hemiparalysis |
| 02/22/2006 | CN1736462A Chinese proprietary medicine making fleece-flower root as main raw material |
| 02/22/2006 | CN1736446A Kidney-tonifying brain-invigorating medicine and preparation process thereof |
| 02/22/2006 | CN1736445A Kidney-tonifying brain-invigorating medicine and preparation process thereof |
| 02/22/2006 | CN1736442A Asthma treating cigarette which can also be used as drug substitute |
| 02/22/2006 | CN1736436A Effervescence tablet of Chinese magnoliavine fruit and its preparation process |
| 02/22/2006 | CN1736433A Ointment for treating tumor and rheumatic paralysis |
| 02/22/2006 | CN1736406A Method for preparing formulation containing Indianmulberry extract |
| 02/22/2006 | CN1736399A Medicine for treating insomnia and improving sleep quality and preparation process thereof |
| 02/22/2006 | CN1736385A Composition containing ganglioside, jphosphatidyl inositol and/or inositol and application thereof |
| 02/22/2006 | CN1736380A Drug addiction-stopping formulation and preparation thereof |
| 02/22/2006 | CN1736374A Application of (R)- flurbiprofenester in pharmacy, injection thereof and method for preparing the same |
| 02/22/2006 | CN1736370A Freeze dried powder injection of tramadol hydrochloride and its preparation process |
| 02/22/2006 | CN1736368A Paeonol soft capsule, its preparing process and application |
| 02/22/2006 | CN1243000C Tocopherols, tocotrienols, other chroman and side chain dervative and uses thereof |
| 02/22/2006 | CN1242995C Novel compounds, their use and preparation |
| 02/22/2006 | CN1242993C Heterocycle derivatives and drugs |
| 02/22/2006 | CN1242991C Aporphine esters and their use in therapy |
| 02/22/2006 | CN1242780C Medicine composition for antagonizing poison-side effect caused by psychotropic drug |
| 02/22/2006 | CN1242778C Medicine for treating cardiovascular and cerebrovascular disease and hemiparalysis |
| 02/22/2006 | CN1242745C Slow release (controlled releuse) preparation of doufuguosu |
| 02/22/2006 | CN1242742C Oryzanol containing soft capsule preparation method |
| 02/21/2006 | US7001920 Psychological disorders; antidepressant |
| 02/21/2006 | US7001917 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents |
| 02/21/2006 | US7001915 Ultrashort-acting opioids for transdermal applications |
| 02/21/2006 | US7001914 Compounds |
| 02/21/2006 | US7001908 Arylpiperazines having activity at the serotonin 1A receptor |
| 02/21/2006 | US7001907 Peptide-containing α-ketoamide cysteine and serine protease inhibitors |
| 02/21/2006 | US7001902 Cyclization in presence of Lawesson's reagent |
| 02/21/2006 | US7001900 Central nervous system disorders |
| 02/21/2006 | US7001898 Treating conditions involving increased vascular resistance and cardiac insufficiency. |
| 02/21/2006 | US7001729 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 02/21/2006 | US7001611 Using astaxanthin; sleep disorders |
| 02/21/2006 | CA2395196C Cyclic amp-specific phosphodiesterase inhibitors |
| 02/21/2006 | CA2250347C Piperazine and piperidine compounds with high affinity for dopamine-d2 and serotonin-5ht1a receptors |
| 02/21/2006 | CA2175372C Novel 9-hydroxy-pyrido[1,2-a]pyrimidin-4-one ether derivatives |
| 02/21/2006 | CA2152486C Anticonvulsant sorbopyranose sulfamates |
| 02/21/2006 | CA2065986C 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1h-indoles, intermediates and a process for their preparation, and their use as medicaments |
| 02/20/2006 | CA2478458A1 Treatment of pediatric multiple sclerosis |
| 02/20/2006 | CA2478455A1 Treatment of severe multiple sclerosis |
| 02/16/2006 | WO2006017614A1 Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| 02/16/2006 | WO2006017406A1 Cyanoamidine p2x7 antagonists for the treatment of pain |
| 02/16/2006 | WO2006017188A2 Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| 02/16/2006 | WO2006016828A2 Use of alpha ketoglutarate for treating alzheimer, parkinson |
| 02/16/2006 | WO2006016707A2 Pyrazolone compounds for treating cerebrovascular disorders |
| 02/16/2006 | WO2006016644A1 Antibody and utilization of the same |
| 02/16/2006 | WO2006016278A1 Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| 02/16/2006 | WO2006016192A2 Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia |
| 02/16/2006 | WO2006015590A2 Novel formulation for l-tryptophane comprising carbidopa/benserazide |
| 02/16/2006 | WO2003033720A8 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| 02/16/2006 | WO2003025129A3 Neurotransmission-associated proteins |
| 02/16/2006 | US20060036089 33 human secreted proteins |
| 02/16/2006 | US20060036074 Bromodomain protein |